The antibiotic resistance crisis, with a focus on the United States

Journal of Antibiotics

Volumn 70, Issue 5, 2017, Pages 520-526

  Martens, Evan ^a   Demain, Arnold L ^b  

^a Cempra Pharmaceuticals Inc   (United States)

^b DREW UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BIOFILM; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DRUG INDUSTRY; ESCHERICHIA COLI; HOSPITALIZATION; METABOLIC ENGINEERING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; UNITED STATES; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES; TRENDS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; UNITED STATES;

EID: 85019621483     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2017.30     Document Type: Review

References (91)

1. Yoneyama, H. & Katsumata, R. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci. Biotechnol. Biochem. 70, 1060-1075 (2006).
2. Heeb,S.et al. Quinolones: from antibiotics to autoinducers. FEMS Microbiol. Rev. 35, 247-274 (2011).
3. Fernandes, P. Antibacterial discovery and development-the failure of success? Nat. Biotechnol. 24, 1497-1503 (2006).
4. Lederberg, J. Pathways of discovery: infectious history. Science 288, 287-293 (2000).
5. Hamaki, T. et al. Isolation of novel bacteria and actinomycetes using soil-extract agar medium. J. Biosci. Bioeng. 99, 485-492 (2005).
6. Ikeda, H. et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat. Biotechnol. 21, 526-531 (2003).
7. Christiansen, K. J. Fusidic acid. Antimicrobe. Available at http://www.antimicrobe.org/ d29.asp (accessed 23 January 2017).
8. Kraus, C. N. Low hanging fruit in infectious disease drug development. Curr. Opin. Microbiol. 11, 434-438 (2008).
9. Scott, R. W. Defensin mimetics: nature knows best. Am. Biotechnol. Lab. 27, 16-19 (2009).
10. Butler, M. S. & Buss, A. D. Natural products-the future scaffolds for novel antibiotics? Biochem. Pharmacol. 71, 919-929 (2006).
11. Centers for Disease Control and Prevention (CDC) Antibiotic/antimicrobial resistance. Available at https://www.cdc.gov/drugresistance/ (accessed 23 January 2017).
12. Walsh, C. T. & Fischbach, M. A. Squashing superbugs - the race for new antibiotics. Sci. Am. 301, 44-51 (2009).
13. Centers for Disease Control and Prevention (CDC) Methicillin-resistant Staphylococcus aureus (MRSA)-general information about MRSA in healthcare settings. Available at https://www.cdc.gov/mrsa/healthcare/index.html#q6 (accessed 24 January 2017).
14. Laxminarayan, R. Antibiotic effectiveness: balancing conservation against innovation. Science 345, 1299-1301 (2014).
15. Centers for Disease Control and Prevention (CDC) Biggest threats. Available at https://www.cdc.gov/drugresistance/biggest-threats.html (accessed 24 January 2017).
16. Ivarsson, M. E., Leroux, J. C. & Castagner, B. Investigational new treatments for Clostridium difficile infection. Drug Discov. Today 20, 602-608 (2015).
17. Singh, S. B. & Barrett, J. F. Empirical antibacterial drug discovery-foundation in natural products. Biochem. Pharmacol. 71, 1006-1015 (2006).
18. Davies, J. Resistance redux. EMBO Rep. 8, 616-621 (2007).
19. McKenna, M. Antibiotic resistance: the last resort. Nature 499, 394-396 (2013).
20. Fernandes, P. & Schranz, J. New macrolides essential to treat CABP. J. Gen. Eng. Biotechnol. News 31, 54-55 (2011).
21. Cain, C. ClpPing Persistence. SciBX 6 (2013).
22. The Scientist staff. Overcoming resistance. Scientist 28, (2014).
23. Erickson, B. House clears chemicals bill. Chem. Eng. News 93, 6 (2015).
24. Ejim, L. et al. Combinations of antibiotics and non-antibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
25. DeWeerdt, S. Vaccines: an age-old problem. Nature 502, 58-59 (2013).
26. Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
27. Maxmen, A. Drug development: a combined effort. Nature 502, 54-56 (2013).
28. Bjarnsholt, T. et al. Applying insights from biofilm biology to drug development-can a new approach be developed? Nat. Rev. Drug Discov. 12, 781-808 (2013).
29. Bald, D. & Koul, A. Advances in discovery of new antibacterials for combating metabolically resting bacteria. Drug Discov. Today 18, 250-255 (2013).
30. Balemans, W. et al. Novel antibiotics targeting respiratory ATP synthesis in Grampositive pathogenic bacteria. Antimicrob. Agents Chemother. 56, 4131-4139 (2012).
31. Spoering, A. L. & Lewis, K. GlpD and PlsB participate in persister cell formation in Escherichia coli. J. Bacteriol. 183, 6746-6751 (2001).
32. Bigger, J. W. Treatment of staphylococcal infections with penicillin by intermittent sterilization. Lancet 244, 497-500 (1944).
33. Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503, 365-370 (2013).
34. Michel, K. H. & Kastner, R. E. A54556 antibiotics and process for production thereof. US Patent 4492650 (1985).
35. Broetz-Oesterhelt, H. et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11, 1082-1087 (2005).
36. Laxminarayan, R. et al. UN high-level meeting on antimicrobials-who do we need? Lancet 388, 218-220 (2016).
37. Drews, J. Quo vadis, biotech? (Part 2). Drug Discov. Today 6, 21-26 (2001).
38. Daemmrich, A. A. & Bowden, M. E. A rising drug industry. Chem. Eng. News 83, 28-42 (2005).
39. Harvey, A. L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 11, 480-484 (2007).
40. Barrett, J. F. Can biotech deliver new antibiotics? Curr. Opin. Microbiol. 8, 498-503 (2005).
41. Ernst & Young The Ernst & Young Fifteenth Annual Report on the Biotechnology Industry (Ernst & Young LLP, Palo Alto, CA, USA, 2000).
42. Watkins, K. J. Fighting the clock. Chem. Eng. News 80, 27-33 (2002).
43. Burrill, G. S. Personalized medicine or block-busterology? BioPharm 15, 46-50 (2002).
44. Bush, K. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 10 (suppl 4), 10-17 (2004).
45. Fox, S., Farr-Jones, S. & Yund, M. A. New directions in drug discovery. Gen. Eng. News 19, 10, 36, 56, 66, 80 (1999).
46. Ausman, D. J. Screening's age of insecurity. Modern Drug Discov. 4, 32-34 (2001).
47. Horrobin, D. F. Realism in drug discovery-could Cassandra be right? Nat. Biotechnol. 19, 1099-1100 (2001).
48. Kingston, D. G. & Newman, D. J. Mother nature's combinatorial libraries: their influence on the synthesis of drugs. Curr. Opin. Drug Discov. Dev. 5, 304-316 (2002).
49. Waldmann, H. & Breinbauer, R. Nature provides the answer. Screening 6, 46-48 (2002).
50. Newman, D. J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51, 2589-2599 (2008).
51. Shlaes, D. M., Projan, S. J. & Edwards, J. E. Jr Antibiotic discovery: state of the state. ASM News 70, 275-281 (2004).
52. Coates, A. R. & Hu, Y. Novel approaches to developing new antibiotics for bacterial infections. Br. J. Pharmacol. 152, 1147-1154 (2007).
53. Baltz, R. H. Renaissance in antibacterial discovery from actinomycetes. Curr. Opin. Pharmacol. 8, 557-563 (2008).
54. Cain, C. in: Antibiotic Resistance, SciBx Special Issue on Antibiotic Resistance. 2-4 (2013).
55. Bush, K. Why it is important to continue antibacterial drug discovery. ASM News 70, 282-287 (2004).
56. Sasidharan, S., Chen, Y., Saravanan, D., Sundram, K. M. & Yoga, L. L. Extraction, isolation and characterization of bioactive compounds from plants' extracts. Afr. J. Tradit. Complement. Altern. Med. 8, 1-10 (2011).
57. Salas, J. A. & Mendez, C. Engineering the glycosylation of natural products in actinomycetes. Trends Microbiol. 15, 219-232 (2007).
58. Pageni, B. B. et al. Genetically engineered biosynthesis of macrolide derivatives including 4-amino-4,6-dideoxy-L-glucose from Streptomyces venezuelaeYJ003-OTBP3. J. Microbiol. Biotechnol. 18, 88-94 (2007).
59. Kren, V. & Rezanta, T. Sweet antibiotics-the role of glycosidic residues in antibiotic and antitumor activity and their randomization. FEMS Microbiol. Rev. 32, 858-889 (2008).
60. Mills, S. D. When will the genomics investment pay off for antibacterial discovery? Biochem. Pharmacol. 71, 1096-1102 (2006).
61. Gross, H. Strategies to unravel the function of orphan biosynthesis pathways: recent examples and future prospects. Appl. Microbiol. Biotechnol. 75, 267-277 (2007).
62. Udwary, D. W. et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinospora tropica. Proc. Natl Acad. Sci. USA 104, 10376-10381 (2007).
63. Zhang, H., Wang, Y. & Pfeifer, B. A. Bacterial hosts for natural product production. Mol. Pharm. 5, 212-225 (2008).
64. Chiang, Y. M. et al. Molecular genetic mining of the Aspergillus secondary metabolome: discovery of the emericellamide biosynthetic pathway. Chem. Biol. 15, 527-532 (2008).
65. Zerkly, M. & Challis, G. L. Strategies for the discovery of new natural products by genome mining. ChemBioChem 10, 625-633 (2009).
66. Lautru, S., Deeth, R. J., Bailey, L. M. & Challi, G. L. Discovery of a new peptide natural product from Streptomyces coelicolor genome mining. Nat. Chem. Biol. 1, 265-269 (2005).
67. Cane, D. E. et al. Geosmin biosynthesis in Streptomyces avermitilis. Molecular cloning, expression and mechanistic study of the germacradienol/geosmin synthase. J. Antibiot. 59, 471-479 (2006).
68. Lin, X., Hopson, R. & Cane, D. E. Genome mining in Streptomyces coelicolor: molecular cloning and characterization of a new sesquiterpene synthase from S. coelicolor. J. Am. Chem. Soc. 128, 6022-6023 (2006).
69. Song, L. et al. Type III polyketide synthase beta-ketoacyl-ACP starter unit and ethylmalonyl-CoA extender unit selectivity discovered by Streptomyces coelicolor genome mining. J. Am. Chem. Soc. 128, 14754-14755 (2006).
70. Park, J. H., Cha, C. J. & Roe, J. H. Identification of genes for mycothiol biosynthesis in Streptomyces coelicolor A3. J. Microbiol. 44, 121-125 (2006).
71. Busti, E. et al. Antibiotic-producing ability by representatives of a newly discovered lineage of actinomycetes. Microbiology 152, 675-683 (2006).
72. Schloss, P. D. & Handelsman, J. Status of the microbial census. Mol. Biol. Rev. 68, 686-691 (2004).
73. Amann, R. I., Ludwig, W. & Schleifer, K. H. Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol. Rev. 59, 143-169 (1995).
74. Mueller, G. M. et al. Global diversity and distribution of macrofungi. Biodivers. Conserv. 16, 37-48 (2007).
75. Hawksworth, J. Mushrooms: the extent of the unexplored potential. J. Med. Mushrooms 3, 333-337 (2001).
76. Vartoukian, S. R., Palmer, R. M. & Wade, W. G. Strategies for culture of 'unculturable' bacteria. FEMS Microbiol. Lett. 309, 1-7 (2010).
77. Hugenholtz, P., Hooper, S. D. & Kyrpides, N. C. Focus: synergistetes. Environ. Microbiol. 11, 1327-1329 (2009).
78. Lorenz, P. & Eck, J. Metagenomics and industrial applications. Nat. Rev. Microbiol. 3, 510-516 (2005).
79. Lefevre, F. et al. Drugs from hidden bugs: their discovery via untapped resources. Res. Microbiol. 159, 153-161 (2008).
80. Simon, C. & Daniel, R. Achievements and new knowledge unraveled by metagenomic approaches. Appl. Microbiol. Biotechnol. 85, 265-276 (2009).
81. Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66, 571-591 (2013).
82. Jabes, D. The antibiotic R&D pipeline: an update. Curr. Opin. Microbiol. 14, 564-566 (2011).
83. Kneller, R. Importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867-882 (2010).
84. U.S. Department of Health & Human Services, Public Health Emergency. Jarrett, E BARDA Broad Spectrum Antimicrobials (BSA) Program. Available at https://www.phe. gov/ASPRBlog/Lists/Posts/Post.aspx?ID=97 (accessed 25 January 2017).
85. Reed, J. C. et al. The NIH's role in accelerating translational sciences. Nat. Biotechnol. 10, 16-19 (2012).
86. Jarvis, L. M. NIH initiative aims to partner academics with pharmaceutical companies to revive failed drug candidates. Chem. Eng. News 90, 41-43 (2012).
87. Roberts, J. P. Incentives aim to boost antibiotic development. Nat. Biotechnol. 30, 735-736 (2012).
88. Fox, J. L. Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31, 379-382 (2013).
89. Cotter, P. D., Ross, P. & Hill, C. Bacteriocins-a viable alternative to antibiotics? Nat. Rev. Microbiol. 11, 95-103 (2013).
90. Olle, B. Medicines from microbiota. Nat. Biotechnol. 31, 309-315 (2013).
91. Fox, J. L. Anti-infective monoclonals step in where antimicrobials fail. Nat. Biotechnol. 31, 952-954 (2013).